Avid Bioservices (NASDAQ: CDMO) reported Q1 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $37.7 million versus the consensus estimate of $37.06 million.

GUIDANCE:

Avid Bioservices sees FY 2024 revenue of $145-165 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.